Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Operating Income: 2017-2025

Historic Operating Income for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to -$40.3 million.

  • Dianthus Therapeutics' Operating Income fell 34.74% to -$40.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$140.3 million, marking a year-over-year decrease of 69.24%. This contributed to the annual value of -$101.9 million for FY2024, which is 111.45% down from last year.
  • According to the latest figures from Q3 2025, Dianthus Therapeutics' Operating Income is -$40.3 million, which was down 15.35% from -$34.9 million recorded in Q2 2025.
  • Over the past 5 years, Dianthus Therapeutics' Operating Income peaked at -$7.7 million during Q1 2023, and registered a low of -$40.3 million during Q3 2025.
  • In the last 3 years, Dianthus Therapeutics' Operating Income had a median value of -$22.2 million in 2024 and averaged -$23.5 million.
  • Data for Dianthus Therapeutics' Operating Income shows a maximum YoY plummeted of 146.34% (in 2024) over the last 5 years.
  • Dianthus Therapeutics' Operating Income (Quarterly) stood at -$10.7 million in 2022, then fell by 21.16% to -$13.0 million in 2023, then crashed by 146.34% to -$31.9 million in 2024, then slumped by 34.74% to -$40.3 million in 2025.
  • Its Operating Income stands at -$40.3 million for Q3 2025, versus -$34.9 million for Q2 2025 and -$33.2 million for Q1 2025.